The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease

Table 1

Patients’ characteristics.

Characteristics	Total patients (N = 95)
Age, y	75 (71–80)
Male sex	68 (72)
CCIS	6 (4–7)
From ILDs diagnosis to AE treatment, days	1102 (229–2103)
From symptom onset to treatment, days	6 (3–15)
Diagnosis of AE
Idiopathic ILDs
IPF	21 (22)
Non-IPF	41 (43)
Secondary ILDS
CTD-ILD	19 (20)
Drug-induced ILD	13 (14)
CHP	1 (1)
Physiological parameter
P/F ratio	268 (188–308)
Biomarkers
LDH (IU/L)	282 (237–404)
SP-D (ng/mL)	233 (139–407)
KL-6 (U/mL)	897 (563–1553)
Treatment
PSL before pulse	21 (22)
PSL pulse	95 (100)
PSL after pulse	77 (82)
Macrolide	20 (21)
Anticoagulant	18 (19)
Outcome
3-month mortality	23 (24)

Results are shown as medians with 25th–75th percentiles or numbers (%). Serum SP-D could be measured in 92 patients (97%). AE, acute exacerbation; CCIS, Charlson Comorbidity Index Score; CTD-ILDs, connective tissue disease-associated ILDs; GGO, ground-glass opacity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den Lungen; LDH, lactate dehydrogenase; P/F ratio; partial pressure of oxygen in arterial blood/fraction of the inspiratory oxygen; PSL, prednisolone; SP-D, surfactant protein-D.